Emergent BioSolutions secures $29 million in international orders

GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE:EBS), a medical countermeasures company with a market capitalization of $424 million and an "GREAT" financial health score according to InvestingPro, has secured new purchase orders valued at $29 million from an international government partner, the company announced Friday.

The orders cover several medical countermeasures including products for smallpox, anthrax and botulism threats. This marks the second procurement this year from the same government partner.

Emergent will receive approximately $26 million in 2025, adding to more than $100 million in sales already generated this year for its medical countermeasures portfolio outside the United States.

"In an increasingly dangerous world, we continue to see countries elevating their investment in defense preparedness," said Joe Papa, president and CEO of Emergent, in a press release statement.

The company specializes in developing, manufacturing and supplying medical countermeasures for national security and public health preparedness. These products are designed to help governments respond to emergencies and protect the public from potential threats. With trailing twelve-month revenue of $852 million and a notably low P/E ratio of 3.13, Emergent presents an interesting value proposition according to InvestingPro analysis, which identifies several additional growth indicators available to subscribers.

Emergent noted that recent commitments by NATO members to raise defense expenditures from two percent to five percent of GDP across various areas supports the company’s international expansion efforts.

The multi-product supply agreement reflects growing government priorities on defense and preparedness measures. The types and quantities of products maintained in government stockpiles depend on population protection needs, available products for potential threats, and government resources and priorities.

Emergent BioSolutions has been developing protective solutions for health threats including smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies for over 25 years. Analysts tracking the stock have set price targets ranging from $12 to $15, suggesting potential upside from current levels. For detailed valuation analysis and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Emergent BioSolutions has secured a series of significant government contracts, highlighting its ongoing partnerships with federal agencies. The company received a $56 million contract modification to supply its ACAM2000 vaccine to the U.S. government, which is expected to boost its total projected sales for the vaccine and related products to more than $120 million this year. Additionally, Emergent BioSolutions was awarded a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) for the supply of TEMBEXA oral suspension, a treatment for human smallpox disease. The FDA’s recent approval of manufacturing scale-up for TEMBEXA supports this contract. Furthermore, a $30 million contract modification was secured for supplying CYFENDUS, an FDA-approved anthrax vaccine, also from BARDA. In light of these developments, H.C. Wainwright has reiterated its Buy rating on Emergent BioSolutions, maintaining a price target of $15. These contracts reflect the company’s strategic focus on expanding its role in public health preparedness.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.